InvestSMART

TrivarX Ltd (ASX: TRI) - Announcements

- Current share price for TRI : $0.008

ASX company news and announcements for TrivarX Ltd (TRI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All TrivarX Ltd (TRI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than TrivarX Ltd (TRI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for TrivarX Ltd (TRI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$9 Letter to Shareholders & Notice of AGM & Proxy Form 27 Oct 2026 12:36PM $0.008 $0.008 fallen by 0%
$9 Syntro Health Appointed to Support Stabl-Im Clinical Program 22 Oct 2026 9:37AM $0.008 $0.008 fallen by 0%
$9 Change of Director's Interest Notice - David Trimboli 14 Oct 2026 3:40PM $0.010 $0.008 fallen by 20%
$9 Change of Director's Interest Notice - Chris Ntoumenopoulos 14 Oct 2026 3:39PM $0.010 $0.008 fallen by 20%
$9 Notification of cessation of securities - TRI 14 Oct 2026 3:34PM $0.010 $0.008 fallen by 20%
$9 Appendix 4G 29 Sep 2026 4:57PM $0.011 $0.008 fallen by 27.27%
$9 Corporate Governance Statement 29 Sep 2026 4:57PM $0.011 $0.008 fallen by 27.27%
$9 2026 Annual Report 29 Sep 2026 4:55PM $0.011 $0.008 fallen by 27.27%
$9 Stabl-Im Clinical Development Update 23 Sep 2026 9:36AM $0.009 $0.008 fallen by 11.11%
$9 Notice of AGM and Closing Date for Director Nominations 22 Sep 2026 9:08AM $0.012 $0.008 fallen by 33.33%
$9 Appendix 4E - Preliminary Final Report 27 Aug 2026 1:05PM $0.015 $0.008 fallen by 46.67%
$9 June 2026 Quarterly Activities Report and Appendix 4C 28 Jul 2026 2:02PM $0.016 $0.008 fallen by 50%
$9 Stabl-Im clinical trial supply milestone achieved 16 Jul 2026 9:15AM $0.020 $0.008 fallen by 60%
$9 Investor Presentation - Stabl-Im program 25 Jun 2026 9:19AM $0.022 $0.008 fallen by 63.64%
$9 Change of Registered Office Address 26 May 2026 2:06PM $0.028 $0.008 fallen by 71.43%
$9 CRO Engaged to Advance Stabl-Im Phase 1 Trial 22 May 2026 9:36AM $0.029 $0.008 fallen by 71.93%
$9 March 2026 Quarterly Activities Report and Appendix 4C 30 Apr 2026 9:38AM $0.018 $0.008 fallen by 55.56%
$9 Dr Danielle Meyrick appointed as CEO 29 Apr 2026 8:29AM $0.016 $0.008 fallen by 50%
$9 Key management changes 5 Mar 2026 9:29AM $0.024 $0.008 fallen by 66.67%
$9 Appendix 4D & Half-Year Financial Report to 31 December 2025 24 Feb 2026 2:53PM $0.023 $0.008 fallen by 65.22%
$9 December 2025 Quarterly Activities Report and Appendix 4C 30 Jan 2026 8:24AM $0.020 $0.008 fallen by 60%
$9 Final Director's Interest Notice - John Mathias 2 Jan 2026 10:29AM $0.019 $0.008 fallen by 57.89%
$9 Ceasing to be a substantial holder 23 Dec 2025 5:38PM $0.017 $0.008 fallen by 52.94%
$9 Becoming a substantial holder - Daniel Tillett 23 Dec 2025 9:27AM $0.017 $0.008 fallen by 52.94%
$9 Second-tranche placement funding completed 22 Dec 2025 11:24AM $0.017 $0.008 fallen by 52.94%

1 - 25 of 218 results

Page 1 of 9

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.